Nasdaq Prld News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq prld. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Prld Today - Breaking & Trending Today

Prelude Highlights Continued Strength of Discovery Engine

Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at. ....

United States , Andrew Combs , Peggy Scherle , Helen Shik , Lindsey Trickett , Shik Communications , Prelude Therapeutics Incorporated Nasdaq , American Association For Cancer Research , Exchange Commission , Therapeutics Incorporated , American Association , Cancer Research , Annual Meeting , Chief Chemistry Officer , Chief Scientific Officer , Preclinical Characterization , Highly Potent , Orally Bioavailable Targeted Protein Degrader , Novel Highly Selective Cyclin Dependent Kinase , Has Potent Antitumor Activity , Various Lymphoid , Brain Penetrant , Highly Effective , Preclinical Models , Breast Cancer , Private Securities Litigation Reform Act ,

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 15.6% in January

Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Free Report) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 522,000 shares, an increase of 15.6% from the January 15th total of 451,500 shares. Based on an average trading volume of 141,000 shares, […] ....

Morgan Stanley , Mirae Asset Global Investments Co , Prelude Therapeutics Incorporated , Barclays Plc , Cubist Systematic Strategies , Jpmorgan Chase Co , Royal Bank , Get Free Report , Prelude Therapeutics , Asset Global Investments , Therapeutics Incorporated , Prelude Therapeutics Daily , Nasdaq Prld ,

Prelude Announces Multiple Clinical and Preclinical Poster

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision. ....

United States , Jane Huang , Peggy Sherle , Helen Shik , Lindsey Trickett , Hynes Convesntion Center , Exchange Commission , Shik Communications , Prelude Therapeutics Incorporated Nasdaq , Therapeutics Incorporated , Molecular Targets , Cancer Therapeutics , Triple Meeting , Chief Medical Officer , Poster Presentations , Chief Scientific Officer , Private Securities Litigation Reform Act , Nasdaq Prld , Prelude Therapeutics , Triple Meeting , Precision Oncology ,

HC Wainwright Weighs in on Prelude Therapeutics Incorporated's Q1 2024 Earnings (NASDAQ:PRLD)

Prelude Therapeutics Incorporated (NASDAQ:PRLD – Free Report) – Stock analysts at HC Wainwright issued their Q1 2024 earnings estimates for Prelude Therapeutics in a research note issued on Thursday, August 17th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.61) per share for the quarter. HC Wainwright currently has a “Buy” rating […] ....

United States , Prelude Therapeutics Incorporated , Blackrock Inc , Orbimed Advisors Llc , America Corp , Morgan Stanley , Vanguard Group Inc , Free Report , Prelude Therapeutics , Prelude Therapeutic , Therapeutics Trading Down , Director Orbimed Advisors Llc , Get Free Report , Therapeutics Incorporated , Prelude Therapeutics Daily , Nasdaq Prld , Earnings Estimates , Hc Wainwright ,

Prelude Therapeutics (NASDAQ:PRLD) Rating Reiterated by HC Wainwright

Prelude Therapeutics (NASDAQ:PRLD – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $17.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 376.19% from the stock’s previous close. Other equities […] ....

Renaissance Technologies , Boxer Capital , Blackrock Inc , Orbimed Advisors Llc , Morgan Stanley , Securities Exchange Commission , Prelude Therapeutics Incorporated , Prelude Therapeutics , Get Free Report , Director Orbimed Advisors Llc , Exchange Commission , Street Corp , Therapeutics Incorporated , Prelude Therapeutics Daily , Nasdaq Prld , Reiterated Rating , Hc Wainwright ,